GSK is currently the market leader in the meningococcal vaccine market, racking up sales of £1.26 billion (almost $1.6 billion) last year across the Bexsero and Menveo brands, but is having to ...

The first dose of the measles-mumps-rubella vaccine is given when children are 12 to 15 months old. Some doctors and parents may opt for earlier doses.

NIH has launched a human trial for LASSARAB, a dual-purpose vaccine targeting Lassa fever and rabies. Early animal studies ...

Viruses like SARS-CoV-2 use sugar molecules to hide from the immune system, but scientists at Scripps Research have designed ...

New biomarker and immune data from the ongoing phase 2 trial with EVX-01 will be presented at the American Association for Cancer Research (AACR) ...

Mount Sinai scientists will continue studying PGV001 in larger groups of patients and testing how it works with other cancer treatments. Data from this phase 1 study have prompted three additional ...

EVM14 received U.S. FDA clearance for its IND application, becoming Everest's first internally discovered program, and the first mRNA therapeutic cancer vaccine to be cleared for global clinical ...

AIM Vaccine Co., Ltd. Class H ( ($HK:6660) ) has provided an update. AIM Vaccine Co., Ltd. has received approval from the U.S. FDA to conduct ...

The company has previously suggested that the 5-in-1 vaccine could eventually become a $1 billion to $2 billion product.

Everest Medicines Ltd. has obtained IND clearance from the FDA for EVM-14, an off-the-shelf mRNA cancer vaccine targeting multiple tumor-associated antigens and designed to treat various cancers, ...